Target：ApoC-III

Fields：PPAR signaling pathway;Cholesterol metabolism

Gene Name：APOC3

Protein Name：Apolipoprotein C-III

Human Gene Id：345

Human Swiss Prot No：P02656

Mouse Swiss Prot No：P33622

Immunogen：The antiserum was produced against synthesized peptide derived from the C-terminal region of human APOC3. AA range:46-95

Specificity：ApoC-III Polyclonal Antibody detects endogenous levels of ApoC-III protein.

Formulation：Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source：Polyclonal, Rabbit,IgG

Dilution：WB 1:500 - 1:2000. IHC: 1:100-1:300. ELISA: 1:10000.. IF 1:50-200

Purification：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Concentration：1 mg/ml

Storage Stability：-15°C to -25°C/1 year(Do not lower than -25°C)

Other Name：APOC3;Apolipoprotein C-III;Apo-CIII;ApoC-III;Apolipoprotein C3

Observed Band(KD)：11kD

Background： Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to delay catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia. [provided by RefSeq, Jul 2008],

Function：disease:Defects in APOC3 may be a cause of hyperalphalipoproteinemia [MIM:143470]. Affected individuals show high levels of alpha-lipoprotein (high density lipoprotein/HDL).,function:Inhibits lipoprotein lipase and hepatic lipase and decreases the uptake of lymph chylomicrons by hepatic cells. This suggests that it delays the catabolism of triglyceride-rich particles.,PTM:O-linked glycan consists of Gal-GalNAc disaccharide, further modified with up to 3 sialic acid residues.,similarity:Belongs to the apolipoprotein C3 family.,tissue specificity:Constitutes 50% of the protein fraction of VLDL and 2% of that of HDL. Synthesized predominantly in liver and to a lesser degree in intestine.,

Subcellular Location：Secreted .

Expression：Liver.